Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants

Vaccine

Volumn 27, Issue 33, 2009, Pages 4439-4446

  Poot, J ^a   Janssen, L H M ^a   van Kasteren Westerneng, T J ^a   van der Heijden Liefkens, K H A ^a   Schijns, V E J C ^a   Heckeroth, A ^b  

^a INTERVET INTERNATIONAL BV   (Netherlands)

^b Intervet Innovation GmbH   (Germany)

Author keywords

Adjuvant; Canine; Histone; Leishmania infantum; Live BCG; Matrix C; MDP; Propionibacterium acnes; Recombinant; Ribosomal protein; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; BCG VACCINE; EPITOPE; EQSTIM; HISTONE; JPCM Q PROTEIN; LEISHMANIA VACCINE; LIVE VACCINE; MATRIX C; MURAMYL DIPEPTIDE; RECOMBINANT PROTEIN; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACULOVIRUS; BODY WEIGHT; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOG; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMORAL IMMUNITY; LEISHMANIA INFANTUM; LEISHMANIASIS; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROPIONIBACTERIUM ACNES; SKIN DEFECT; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BASE SEQUENCE; CELL PROLIFERATION; DOG DISEASES; DOGS; EPITOPES; FEMALE; HISTONES; HYPERSENSITIVITY, DELAYED; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MALE; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM BOVIS; RECOMBINANT PROTEINS; RIBOSOMAL PROTEINS;

EID: 67649470385     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.043     Document Type: Article

References (29)

1. Baneth G., and Shaw S.E. Chemotherapy of canine leishmaniosis. Vet. Parasitol. 106 (2002) 315-324
2. Baldi L., Mizzoni V., and Guarino A. Canine leishmaniasis in Campania: new and old foci. Parassitologia 46 (2004) 217-220
3. Capelli G., Baldelli R., Ferroglio E., Genchi C., et al. Monitoring of canine leishmaniasis in northern Italy: an update from a scientific network. Parassitologia 46 (2004) 193-197
4. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 55 (1996) 125-130
5. Melby P.C., Ogden G.B., Flores H.A., Zhao W., et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68 (2000) 5595-5602
6. Probst P., Stromberg E., Ghalib H.W., Mozel M., et al. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J. Immunol. 166 (2001) 498-505
7. Soto M., Requena J.M., Quijada L., Guzman F., et al. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Immunol. Lett. 48 (1995) 23-28
8. Soto M., Requena J.M., Quijada L., Perez M.J., et al. Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Clin. Exp. Immunol. 115 (1999) 342-349
9. Soto M., Requena J.M., Quijada L., Garcia M., et al. Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol. Lett. 48 (1995) 209-214
10. Goswami A., Chatterjee S., and Sharma S. Cloning of a ribosomal phosphoprotein P0 gene homologue from Plasmodium falciparum. Mol. Biochem. Parasitol. 82 (1996) 117-120
11. Sehgal A., Kumar N., Carruthers V.B., and Sharma S. Translocation of ribosomal protein P0 onto the Toxoplasma gondii tachyzoite surface. Int. J. Parasitol. 33 (2003) 1589-1594
12. Soto M., Requena J.M., Quijada L., Angel S.O., et al. During active viscerocutaneous leishmaniasis the anti-P2 humoral response is specifically triggered by the parasite P proteins. Clin. Exp. Immunol. 100 (1995) 246-252
13. Iborra S., Soto M., Carrion J., Nieto A., et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect. Immun. 71 (2003) 6562-6572
14. Iborra S., Soto M., Carrion J., Alonso C., et al. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine 22 (2004) 3865-3876
15. Iborra S., Carrion J., Anderson C., Alonso C., et al. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect. Immun. 73 (2005) 5842-5852
16. Molano I., Alonso M.G., Miron C., Redondo E., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 92 (2003) 1-13
17. Champsi J., and McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56 (1988) 3272-3279
18. Hill J.O. Modulation of the pattern of development of experimental disseminated leishmaniasis by Corynebacterium parvum. J. Leukoc. Biol. 41 (1987) 165-169
19. Mitchell G.F., and Handman E. Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility. Aust. J. Exp. Biol. Med. Sci. 61 (1983) 11-25
20. Rivier D., Bovay P., Shah R., Didisheim S., et al. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol. 21 (1999) 461-473
21. Sjolander A., Baldwin T.M., Curtis J.M., Bengtsson K.L., et al. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16 (1998) 2077-2084
22. Pearse M.J., and Drane D. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine 22 (2004) 2391-2395
23. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 22 (2004) 3658-3668
24. Peacock C.S., Seeger K., Harris D., Murphy L., et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 39 (2007) 839-847
25. Schaller A., Kuhn R., Kuhnert P., Nicolet J., et al. Characterization of apxIVA, a new RTX determinant of Actinobacillus pleuropneumoniae. Microbiology 145 Pt 8 (1999) 2105-2116
26. Berens R.L., Brun R., and Krassner S.M. A simple monophasic medium for axenic culture of hemoflagellates. J. Parasitol. 62 (1976) 360-365
27. Poot J., Rogers M.E., Bates P.A., and Vermeulen A. Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs. Vet. Parasitol. 130 (2005) 41-53
28. Schetters T.P., and Gravendyck M. Regulations and procedures in parasite vaccine development. Parasitology 133 Suppl (2006) S189-S195
29. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., et al. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I. R. Iran. Vaccine 22 (2004) 4097-4100